BiotechTube

GRC 17356 + Matching Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Painful Diabetic Peripheral Neuropathy

Conditions

Painful Diabetic Peripheral Neuropathy

Trial Timeline

Nov 1, 2012 → Sep 1, 2014

NCT ID
NCT01726413

About GRC 17356 + Matching Placebo

GRC 17356 + Matching Placebo is a phase 2 stage product being developed by Glenmark Pharmaceuticals for Painful Diabetic Peripheral Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01726413. Target conditions include Painful Diabetic Peripheral Neuropathy.

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Peripheral Neuropathy were approved

Approved (7) Terminated (2) Active (11)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅duloxetine hydrochlorideEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
✅pregabalinPfizerApproved
✅PregabalinPfizerApproved
✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01726413Phase 2Completed

Competing Products

20 competing products in Painful Diabetic Peripheral Neuropathy

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43
duloxetine hydrochlorideEli LillyApproved
43
Duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
43
Duloxetine + Pregabalin + PlaceboEli LillyPhase 3
40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + PlaceboGlenmark PharmaceuticalsPhase 2
27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)Johnson & JohnsonPhase 3
32
AZD5213 + pregabalin + Placebo + pregabalin capsulesAstraZenecaPhase 2
35
MEDI7352AstraZenecaPhase 2
27
MEDI7352AstraZenecaPhase 2
35
MEDI7352 + PlaceboAstraZenecaPhase 1
29
MK-6096 + PlaceboMerckPhase 2
35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochlorideMerckPhase 2
27
EMA401 + PlaceboNovartisPhase 2
27
PregabalinPfizerPhase 3
40